narciclasine

Narciclasine is an **isocarbostyril alkaloid** isolated from plants in the Amaryllidaceae family, exhibiting potent selective cytotoxicity against cancer cells at nanomolar concentrations through inhibition of protein biosynthesis at the ribosome's peptidyl transferase center and direct binding to eukaryotic translation elongation factor eEF1A (eEF1A), disrupting actin cytoskeleton regulation and cell migration via RhoA activation. It demonstrates strong antitumor efficacy in preclinical models, particularly brain tumors and primary effusion lymphoma (PEL), induces apoptosis via Fas/DR4 pathways, inhibits topoisomerase I, and suppresses inflammation by blocking TNF-α production and NFκB-dependent transcription without affecting NFκB activation; additional activities include antiviral effects against flaviviruses and modulation of Rho/Rho kinase/LIM kinase/cofilin signaling. Despite promising in vivo tumor growth inhibition and survival benefits in mouse xenografts, it remains preclinical due to toxicity at higher doses (NOAEL 1 mg/kg/day orally in rats).[1][2][4][5][6][11][13]

Other names

lycoricidinol